Congressional Testimony 2003

-

November

11/20/2003 Drug Importation
John M. Taylor, III, Associate Commissioner for Regulatory Affairs, Food and Drug Administration, before the Senate Committee on Commerce, Science and Transportation
11/19/2003 Vaccine Research
Lester M. Crawford, D.V.M, Ph.D., Deputy Commissioner of Food and Drugs, before the Senate Committee on Governmental Affairs
11/13/2003 Dietary Supplements
William Egan, Acting Director, Office of Vaccine Research and Review, Center for Biologics Evaluation and Research, before the Senate Committee on Government Reform

-

10/28/2003 Dietary Supplements: Protecting Americans from Potential Adverse Health Risks
John M. Taylor, Associate Commissioner for Regulatory Affairs Food and Drug Administration, before the Senate Committee on Commerce
10/23/2003 Federal and State Role in Pharmacy Compounding and Reconstitution: Exploring the Right Mix to Protect Patients
Steven K. Galson, M.D., M.P.H., Acting Director of the Food and Drug Administration before the Senate Committee on Health, Education, Labor and Pensions

-

08/01/2003 Drug Price Competition and Patent Term Restoration Act of 1984 (Hatch-Waxman Amendments)
Daniel E. Troy, Chief of Counsel of the Food and Drug Administration before the Committee on Judiciary

-

07/24/2003 Ephedrine Alkaloid-Containing Dietary Supplements
Mark B. McClellan, M.D., Ph.D., before the Senate Subcommittee on Commerce, Trade and Consumer Protection and the Subcommittee on Oversight and Investigations, Committee on Energy and Commerce
07/24/2003 Counterterrorism Activities
Mark B. McClellan, M.D., Ph.D., before the Committee on Health, Education, Labor, and Pensions
07/22/2003 Regulating Prescription Drug Promotion
Janet Woodcock, M.D., before the Senate Special Committee on Aging
07/17/2003 FDA's Role in the National Response to an Emerging zoonotic or Secondarily Transmitted Infectious Disease
Lester M. Crawford, D.V.M, Ph.D., before the Committee on Environment and Public Works
07/10/2003 Collaborative Efforts to Facilitate Cancer Drug Development
Theresa M. Mullin, Ph.D, before the House Committee on Energy and Commerce, Subcommittee on Health
07/09/2003 Technology and Innovation: Their Effects on Cost Growth of Healthcare
Mark B. McClellan, M.D., Ph.D., before the Committee on Joint Economics

-

06/24/2003 Imported, Counterfeit, and Unapproved Drugs
John M. Taylor, III, before the House Committee on Energy and Commerce, Subcommittee on Oversight and Investigations
06/17/2003 FTC Study: Generic Drug Entry Prior to Patent Expiration
Daniel E. Troy, before the Senate Committee on the Judiciary
06/17/2003 Regulation of Foods Derived From Plants
Lester M. Crawford, D.V.M., Ph.D., before the House Committee on Agriculture, Subcommittee on Conservation, Credit, Rural Development, and Research
06/12/2003 Safety of Prescription Drugs From Foreign Sources
William K. Hubbard, before the House Committee on Government Reform, Subcommittee on Human Rights and Wellness

-

05/14/2003 Tissue Banks: The Dangers of Tainted Tissues and the Need for Federal Regulation
Jesse L. Goodman, M.D., M.P.H., before the Senate Committee on Governmental Affairs
05/07/2003 FDA Efforts to Combat the SARS Outbreak
Murray M. Lumpkin, M.D. M.Sc., before the House Committee on Energy and commerce, Subcommittee on Oversight and Investigations

-

04/03/2003 International Prescription Drug Parity
William K. Hubbard, before the House Committee on Government Reform, Subcommittee on Human Rights and Wellness

-

03/27/2003 Benefits and Risks of the Sale of Drugs via the Internet
William K. Hubbard, before the House Committee on Government Reform
03/10/2003 South Florida Access to Affordable Prescription Drugs: Costs and Benefits of Alternative Solutions
John M. Taylor, before the House Committee on Energy and Commerce, Subcommittee on Oversight and Investigations
03/06/2003 FY 2004 FDA Budget Request
Mark B. McClellan, MD, Ph.D., before the House Committee

-